Clinical trials: Glycemic Control
Diabetes Mellitus Type 2, Adult-onset Diabetes
Automated SMS-Based Appointment Validation Tool
Medic Mobile conceptualized and proposed the creation of an SMS-based appointment validation tool to automate appointment confirmation and rescheduling.
- Trial name
- NCT01671189
- Testing
- SMS Reminder Software Tool
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Medic Mobile
Diabetes Mellitus, Non-Insulin-Dependent
MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)
The phase III clinical trial examines the efficacy, safety, and tolerability of the addition of MK0431/ONO-5435 to Japanese patients with type 2 diabetes mellitus (T2DM) who have inadequate glycemic control on diet/exercise…
- Trial name
- NCT00837577
- Testing
- Sitagliptin, Voglibose
- Volunteers
- 133 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone
The purpose of this clinical research study is to learn whether a muraglitazar-metformin combination is at least as effective as a glimepiride-metformin combination to treat type 2 diabetics who are not sufficiently controlled…
- Trial name
- NCT00095030
- Testing
- muraglitazar
- Where
- 206 sites in United States, Argentina and 15 more
- Volunteers
- 1,752 people
- Sponsor
- Bristol-Myers Squibb
Type 2 Diabetes
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise
The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can improve (decrease) blood glucose values in Asian patients with Type 2 Diabetes who have never been treated with medication or have been on…
- Trial name
- NCT01095653
- Testing
- Dapagliflozin, Metformin
- Where
- 39 sites in China, India and 2 more
- Volunteers
- 1,179 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Diet and Exercise
Primary Objective: To demonstrate the superiority of sotagliflozin dose 1 versus placebo on hemoglobin A1c (HbA1c) reduction in Chinese patients with type 2 diabetes (T2D) who have inadequate glycemic control on diet and…
- Trial name
- NCT03760965
- Testing
- sotagliflozin (SAR439954)
- Where
- 29 sites in China
- Volunteers
- 276 people
- Sponsor
- Sanofi
Critical Illness
Blood Glucose Control Over an Extended Glucose Control Range in Postoperative Cardiac Surgery Patients in the Intensive Care Unit
Hyperglycaemia is commonly found in critically ill patients. Clinical studies demonstrated that tight blood glucose control in medical and surgical ICU patients results in a significant better outcome for the patients.
- Trial name
- Aldea_02 (NCT00882427)
- Testing
- enhanced model predictive control algorithm (eMPC)
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- B. Braun Melsungen AG
Type 2 Diabetes Mellitus
A Randomized Controlled Trial to Compare the Glycemic Control, With or Without the Connected Solution, of Adult Type 2 Diabetic Participants on Basal Insulin in Taiwan
The Connected Solution investigated in this study is the combination of the titration module "Insultrate" and a cell phone application (app) named Health2Sync (H2S) that synchronizes participants' self-monitoring blood glucose…
- Trial name
- TW CES RCT (NCT05684341)
- Testing
- Connected Solution with H2S app which connects with blood glucose meter (BGM)
- Where
- 14 sites in Taiwan
- Volunteers
- 200 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 10773 at two different doses compared to placebo during long term treatment (78 weeks) in combination with basal insulin in patients…
- Trial name
- NCT01011868
- Testing
- BI 10773 low dose, BI 10773 high dose
- Where
- 99 sites in United States, Denmark and 5 more
- Volunteers
- 494 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 4
A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control
Primary Objective: To demonstrate the superiority of sotagliflozin 400 milligrams (mg) versus placebo with respect to hemoglobin A1c (HbA1c) reduction at Week 26 in participants with Type 2 diabetes who have inadequate glycemic…
- Trial name
- SOTA-CKD4 (NCT03242018)
- Testing
- Sotagliflozin
- Where
- 106 sites in United States, Argentina and 13 more
- Volunteers
- 277 people
- Sponsor
- Lexicon Pharmaceuticals
Type 2 Diabetes
Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients
Phase 3 study to assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients
- Trial name
- NCT05226897
- Testing
- YYC405-T, Metformin≥1000mg, Dapagliflozin 10mg
- Where
- South Korea
- Volunteers
- 256 people
- Sponsor
- Yooyoung Pharmaceutical Co., Ltd.